
Cronos Group CRON
$ 2.79
-0.54%
Quarterly report 2026-Q1
added 05-11-2026
Cronos Group Interest Expense 2011-2026 | CRON
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Cronos Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -241 K | -301 K | 1.03 M | 13 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 M | -301 K | 125 K |
Quarterly Interest Expense Cronos Group
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 K | -283 K | -1 K | 43 K | -315 K | 248 K | -652 K | 966 K | -26 K | 85 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 966 K | -652 K | 7.5 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
501 K | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
496 K | $ 5.76 | -1.37 % | $ 85.6 M | ||
|
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
134 K | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
2.4 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
47 K | $ 33.97 | -2.09 % | $ 1.25 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | ||
|
Pacira BioSciences
PCRX
|
-373 K | $ 23.12 | 1.99 % | $ 1.07 B | ||
|
Organogenesis Holdings
ORGO
|
-5 K | $ 2.47 | -0.6 % | $ 313 M | ||
|
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.02 | -1.92 % | $ 110 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 1.16 | -4.13 % | $ 1.44 M | ||
|
Solid Biosciences
SLDB
|
824 K | $ 6.75 | -6.84 % | $ 591 M | ||
|
Jupiter Wellness
JUPW
|
152 K | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
46.6 M | $ 4.88 | -6.07 % | $ 3.02 B | ||
|
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | ||
|
Evolus
EOLS
|
-539 K | $ 6.45 | -2.27 % | $ 416 M | ||
|
Sundial Growers
SNDL
|
81 K | $ 1.44 | 0.35 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
54.2 M | $ 8.12 | -3.68 % | $ 434 M | ||
|
cbdMD
YCBD
|
34.3 K | $ 0.73 | -2.6 % | $ 2.94 M | ||
|
Veru
VERU
|
768 K | $ 3.78 | -10.64 % | $ 55.4 M | ||
|
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
2.78 M | $ 23.46 | 0.02 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
-174 K | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
-142 M | $ 5.31 | 1.24 % | $ 1.97 B | ||
|
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
5.15 M | $ 5.87 | -7.05 % | $ 232 M | ||
|
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
3.13 M | $ 4.68 | -4.1 % | $ 234 M | ||
|
Viatris
VTRS
|
471 M | $ 16.0 | 0.6 % | $ 18.6 B | ||
|
Zomedica Corp.
ZOM
|
-144 K | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
27 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-623 K | $ 0.65 | -6.64 % | $ 23.4 M | ||
|
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
27.3 K | $ 0.82 | -0.66 % | $ 3.52 M | ||
|
TherapeuticsMD
TXMD
|
300 K | $ 1.99 | -0.75 % | $ 23 M |